Please check your internet connection and try again.
# Hyoscine butylbromide
## Overview
Hyoscine butylbromide (Scopolamine butylbromide) is a peripherally acting quaternary ammonium antispasmodic. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier effectively and does not produce significant central nervous system effects. It acts as an antimuscarinic agent on the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal, biliary, or genitourinary smooth muscle spasms (e.g., irritable bowel syndrome, biliary colic).
* Diagnostic procedures/radiology (as a diagnostic aid).
* *Note: Availability varies significantly by region (not FDA-approved in the US).*
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum daily dose: 80–100 mg.
* **IV/IM/SC:** 20 mg as a single dose. May be repeated after 30 minutes if necessary. Maximum daily dose: 100 mg.
* **Diagnostic Aid (IV):** 20–40 mg administered intravenously.
## Pediatric Dosing
* **Children 6–12 years:** 10 mg orally three times daily.
* **IV/IM/SC:** In severe cases, 0.3–0.6 mg/kg (up to 10 mg) may be administered.
* *Note: Always verify local hospital/regional protocols as pediatric guidance varies significantly.*
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized adjustment guidelines exist; use with caution. Reduced doses are recommended in elderly patients or those with severe impairment to avoid systemic accumulation.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon or intestinal obstruction (paralytic ileus).
* Narrow-angle glaucoma.
* Tachycardia or unstable cardiovascular conditions.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Dry mouth, visual disturbances (mydriasis, blurred vision), tachycardia, constipation, and urinary retention.
* **Serious:** Anaphylaxis, hypersensitivity reactions, and increased intraocular pressure.
## Key Drug Interactions
* **Antihistamines/Tricyclic Antidepressants/Antipsychotics:** May enhance anticholinergic effects.
* **Metoclopramide:** Antagonistic pharmacodynamic effect; avoid concurrent use.
* **Beta-agonists:** May increase tachycardia effects of beta-adrenergic drugs.
## Monitoring
* Monitor heart rate (risk of tachycardia).
* Assess for urinary retention, particularly in elderly men with prostate concerns.
* Monitor ocular symptoms; urgent evaluation is required if eye pain or blurred vision occurs.
## Clinical Pearls
* **Site of action:** Due to its quaternary ammonium structure, it has poor oral bioavailability and low CNS penetration, limiting systemic side effects compared to non-quaternary agents.
* **Injection:** When administered intravenously, push slowly to prevent transient hypotension or tachycardia.
* **Non-US status:** In countries where it is unavailable, clinicians often utilize alternative antispasmodics (e.g., dicyclomine) or anticholinergics, which carry a higher burden of CNS side effects.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug availability, indications, and dosing protocols vary by country and institution. Always verify dosages, contraindications, and compatibility against current local prescribing information, institutional formulary guidelines, or a validated clinical database (e.g., BNF, Lexicomp, UpToDate) before administering medication.
